Hanall Biopharma Co., Ltd. (009420.KS)
| Previous Close | 34,450.00 |
| Open | 34,500.00 |
| Bid | 34,800.00 x 0 |
| Ask | 34,850.00 x 0 |
| Day's Range | 34,050.00 - 36,100.00 |
| 52 Week Range | 18,400.00 - 46,750.00 |
| Volume | |
| Avg. Volume | 632,154 |
| Market Cap | 1.762T |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Apr 29, 2024 - Apr 30, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 43,000.00 |
PR NewswireHanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update
HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for 2023 and provided business updates.
- PR Newswire
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals to Showcase Ongoing Parkinson's Disease Program at the 7th Annual Sachs Associates Neuroscience Innovation Forum
HanAll Biopharma (KRX: 009420.KS), Daewoong Pharmaceutical (KRX: 069620.KS), and NurrOn Pharmaceuticals announced their participation in the 7th Annual Sachs Associates Neuroscience Innovation Forum. The event is scheduled to take place on January 7th, 2024, at the historic Marines' Memorial Club in San Francisco, California. The forum immediately precedes the JP Morgan Healthcare Conference, beginning January 8th.
- PR Newswire
HanAll Biopharma's Partner, NurrOn Pharmaceuticals Incorporated Appoints Dr. Almira Chabi, MD, EGMP to Board of Directors
HanAll Biopharma's partner NurrOn Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related human disorders, is pleased to announce the appointment of Dr. Almira Chabi, MD, EGMP to its Board of Directors, effective November 24, 2023.
